News: Portfolio 2008

TETRALOGIC PHARMACEUTICALS APPOINTS DR. ANDREW PECORA AS CHAIRMAN OF THE BOARD

(continued)

Dr. Pecora has authored and co-authored numerous articles, abstracts, books, chapters and monographs and is a frequent lecturer in the field of cancer. Prior to joining Hackensack Medical Center he was a hematology-oncology Fellow at Memorial Sloan-Kettering Cancer Center in New York. Dr. Pecora is licensed to practice Medicine in both New Jersey and New York and is a Professor of Medicine at UMDNJ.

 

About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held company focused on discovering and developing drugs that modulate cell death pathways. Its lead program, IAP antagonists to treat cancer, is in preclinical development. Other cell death pathway drug discovery programs are at an earlier stage of development. To date, TetraLogic

 

has raised a total of $44 million through private financings. The Company’s investors include
Amgen Ventures, HealthCare Ventures, Kammerer Associates, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and the Vertical Group. For additional information, please refer to the Company’s website at www.tetralogicpharma.com.

Page: 1 2